AGuIX Gadolinium-Based Nanoparticles is under clinical development by NH TherAguix and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AGuIX Gadolinium-Based Nanoparticles’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AGuIX Gadolinium-Based Nanoparticles overview
AGuIX is under development for the treatment of metastatic brain tumor, cervical cancer, non-small cell lung cancer, pancreatic cancer, glioblastoma, melanoma, gastrointestinal cancer, HER2 positive breast cancer, and colorectal cancer. The therapeutic candidate is a radiation sensitizer comprising of gadolinium-chelated polysiloxane based nanoparticles. It is administered through intravenous route.
NH TherAguix overview
NH TherAguix is a clinical stage pharmaceutical company that develops nanomedicine to treat cancer. It offers AGuIX, a radio sensitizer and radio enhancer drug that contains gadolinium nanoparticles, which help improve the localization of solid tumors and the results of radiation therapy. NH TherAguix’s AGuIX causes an increase in tumor contrast following injection, which enables physicians to localize and identify the tumor region. The company’s pipeline portfolio includes Phase I entities, nanocol for cervical cancer; nanorad for brain metastasis treatment; and other pipeline products for glioblastoma, lung, head and neck cancers. NH TherAguix is headquartered in Villeurbanne, Auvergne, France.
For a complete picture of AGuIX Gadolinium-Based Nanoparticles’s drug-specific PTSR and LoA scores, buy the report here.